The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...
The following is a summary of “Anakinra improves retention rate of targeted treatments in Erdheim-Chester disease,” published ...
Class 2 MAP2K1 mutants occasionally but not universally co-occur with other MAPK driver mutations and can be effectively inhibited with FDA-approved MEK inhibitors. 13 In our AACR GENIE cohort, ...
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...
Pfizer’s BREAKWATER trial of Braftovi combo regimen demonstrates improved response in patients with BRAF V600E-mutant metastatic colorectal cancer: New York Tuesday, January 28, ...
A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic ...
tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of PAS-004 in patients with MAPK pathway-driven advanced solid tumours with a documented RAS, NF1 or RAF mutation or ...
NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition (NCT06299839). About Pasithea Therapeutics Corp. Pasithea ...
NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition (NCT06299839). About Pasithea Therapeutics Corp. Pasithea is a biotechnology company focused on the discovery, research and ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback